We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
The awarded projects will study the immune response to HIV and the VIGex tool as a biomarker for immunotherapy response.
Vall d'Hebron has been awarded two of the prestigious Gilead Biomedical Research Grants in its 10th edition, which recognize excellent projects in HIV, COVID-19, Viral Hepatitis C and Delta, Invasive Fungal Infections, B-Cell Lymphomas, and Medical Oncology. The pharmaceutical company Gilead Sciences, in collaboration with the Carlos III Health Institute (ISCIII), held the awards ceremony for the 10th edition of the Gilead Biomedical Research Grants at the Teatro Real in Madrid.
The awarded projects are led by Dr. Meritxell Genesca Ferrer from Vall d'Hebron Research Institute (VHIR) and Dr. Alberto Hernando Calvo from Vall d'Hebron Institute of Oncology (VHIO).
The innate immune response to HIV infection study
Dr. Meritxell Genesca Ferrer, principal investigator of the Infectious Diseases Research Group at VHIR, received a grant to study the initial innate immune response to HIV infection in the female genital mucosa. This project aims to better understand the mechanisms involved in the early stages of HIV infection, especially how mucosal immunity is affected by exposure to the virus. Using human cervical explant models, her team will investigate the interaction between myeloid cells and unconventional T cells to identify potential pathways for infection prevention.
Validation of the VIGex tool as a biomarker for immunotherapy response
Dr. Alberto Hernando Calvo, medical oncologist at the Molecular Cancer Therapy Unit (UITM-CaixaResearch) at VHIO, was awarded another grant to validate VIGex, a tool developed to classify tumours based on their immune response. This biomarker will help identify which patients are more likely to respond to immunotherapy in clinical trials. The VIGex tool is based on the gene expression of 12 key genes and is an innovation driven by VHIO and the Princess Margaret Cancer Center in Toronto.
The Gilead Biomedical Research Grants, in their 10th edition, selected 19 excellent projects with a total investment of one million euros. These grants are a benchmark in the field of research, driving scientific innovation in collaboration with the Carlos III Health Institute and other entities. This recognition reaffirms Vall d'Hebron's commitment to cutting-edge biomedical research, aiming to provide solutions to the major medical challenges of our time.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.